SCHEMBL3613667

SCHEMBL3613667

Cc1nn(C)c(Oc2cc(OCc3ccccc3)c(Cl)cc2C2OCCO2)c1C=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
EGFR P00533 1/20 0.36
KMO O15229 2/20 0.35
RHEB Q15382 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 1/20 0.33
AKR1B1 P15121 1/20 0.33
GPBAR1 Q8TDU6 2/20 0.33
PTGER1 P34995 2/20 0.33
HPGD P15428 1/20 0.33
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
MAPT P10636 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607830 0.97 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3609621 0.88 RHEB (0.38) SMN1; SMN2KMORHEBMEN1KMT2A
SCHEMBL3606715 0.86 RHEB (0.36) SMN1; SMN2KMORHEBMEN1KMT2A
SCHEMBL3608988 0.82 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3607091 0.81 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3612420 0.76 SMN1; SMN2 (0.53) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1
SCHEMBL3599357 0.75 CYP1A2 (0.45) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1
SCHEMBL3610763 0.71 KMO (0.44) SMN1; SMN2KMORHEBNPC1RAB9A
SCHEMBL3616401 0.71 SMN1; SMN2 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3616398 0.71 SMN1; SMN2 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R CYP1A2 137/4885CYP2C9 145/4885CYP2C19 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.